Brought to you by 
Baxalta Incorporated
http://www.baxalta.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Baxalta Incorporated
ICER Enhanced Patient Engagement Program Will Be Led By Former Biopharma Exec
Yvette Venable has more than 20 years’ experience in patient advocacy, heath policy and biopharma communications.
Evotec Extends Takeda Pact to Gene Therapy
Evotec is building a gene therapy R&D center manned by ex-Takeda scientists and has already landed a multi-year drug discovery pact for it with their former Japanese employer.
Novo Nordisk Halts Phase III Concizumab Hemophilia Trials After Three Thrombotic Events
No new patients will be enrolled, and trial participants will stop treatment with the tissue factor pathway inhibitor antibody, a class with four prior suspended hemophilia programs.
Recordati's Isturisa Approved For Cushing's In EU
Acquired from Novartis last year, Isturisa is forecast to have peak sales of over $100m. Now all eyes will be on a PDUFA date in March.
Company Information
- Other Names / Subsidiaries
-
- AesRX LLC
- Chatham Therapeutics
- Gambro AB
- Immuno-US
- Prism Pharmaceuticals, Inc.
- SuppreMol GmbH
- Synovis Life Technologies, Inc.
- Thunderbolt, Inc.
- Vitesse Biologics, LLC